Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Rating of "Hold" by Analysts

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Free Report) have received a consensus rating of "Hold" from the fifteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $106.08.

A number of equities research analysts have recently weighed in on ITCI shares. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and boosted their price objective for the company from $119.00 to $132.00 in a report on Friday, January 31st. Baird R W downgraded Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Royal Bank of Canada restated a "sector perform" rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, January 14th. Finally, Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th.

Intra-Cellular Therapies Price Performance

NASDAQ ITCI traded down $0.01 during trading on Wednesday, hitting $131.24. The company's stock had a trading volume of 1,259,934 shares, compared to its average volume of 1,292,003. Intra-Cellular Therapies has a fifty-two week low of $63.30 and a fifty-two week high of $131.36. The company has a market cap of $13.95 billion, a PE ratio of -150.85 and a beta of 0.72. The business's 50 day simple moving average is $119.20 and its 200-day simple moving average is $93.44.

Remove Ads

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last released its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Analysts expect that Intra-Cellular Therapies will post -0.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its stake in shares of Intra-Cellular Therapies by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company's stock valued at $1,878,000 after purchasing an additional 2,157 shares in the last quarter. Barclays PLC increased its position in shares of Intra-Cellular Therapies by 282.0% in the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock valued at $2,521,000 after buying an additional 25,435 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Intra-Cellular Therapies by 31.9% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company's stock worth $33,258,000 after buying an additional 109,892 shares during the period. Oak Ridge Investments LLC lifted its position in shares of Intra-Cellular Therapies by 74.1% during the 4th quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company's stock valued at $1,656,000 after buying an additional 8,440 shares in the last quarter. Finally, Cynosure Group LLC grew its stake in Intra-Cellular Therapies by 161.0% in the 3rd quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company's stock valued at $1,057,000 after acquiring an additional 8,909 shares during the period. Institutional investors and hedge funds own 92.33% of the company's stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.